Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…Abstract Number: 2761 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Parenchymal Neurological Involvement in Behcet’s Syndrome Patients with Panuveitis
Background/Purpose Behcet’s Syndrome (BS) is a systemic vasculitis which may involve multiple organ systems simultaneously. Most frequently, clinical findings in BS fit into well recognized…Abstract Number: 2762 • 2014 ACR/ARHP Annual Meeting
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
Background/Purpose: Central nervous system involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB)…Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…Abstract Number: 2764 • 2014 ACR/ARHP Annual Meeting
S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes
Background/Purpose: Reversible Cerebral Vasoconstriction Syndromes (RCVS) are a group of disorders characterized by acute onset of recurrent thunderclap headaches with or without neurologic deficits. Radiologically,…Abstract Number: 2765 • 2014 ACR/ARHP Annual Meeting
Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome
Putative blood biomarkers of Reversible Cerebral Vasoconstriction Syndrome Background/Purpose The pathophysiology and molecular mechanisms of Reversible Cerebral Vasoconstriction Syndrome (RCVS) are unknown. Objective of the…Abstract Number: 2766 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil in the Treatment of Primary Central Nervous System Vasculitis
Background/Purpose . The optimal management of primary central nervous system vasculitis (PCNSV) remains unclear. Cyclophosphamyde (CYC) in combination with glucocorticoids (GCs) or GCs alone are…Abstract Number: 2767 • 2014 ACR/ARHP Annual Meeting
Core Outcome Domains and Potential Measurement Instruments in polymyalgia Rheumatica (PMR) Using Omeract Filter 2.0
Background/Purpose The OMERACT PMR specialist interest group was established to develop a core outcome measurement set for PMR using the methods of OMERACT filter 2.0.…Abstract Number: 2768 • 2014 ACR/ARHP Annual Meeting
Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone
Background/Purpose Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder of the elderly, characterised by morning stiffness, pain and aching in the hip and shoulder girdles…Abstract Number: 2769 • 2014 ACR/ARHP Annual Meeting
Validation of New 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study
Background/Purpose: To evaluate the diagnostic and discriminative ability of the new 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) polymyalgia rheumatica (PMR) classification…Abstract Number: 2770 • 2014 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?
Background/Purpose Large Vessel Vasculitis (LVV) can present with heterogeneous clinical manifestations, which range from general symptoms (fever, loss of weight) to the classic symptoms of …Abstract Number: 2771 • 2014 ACR/ARHP Annual Meeting
PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica
Background/Purpose Previously we described antibodies against ferritin heavy chain peptide (anti-FHCP) in sera of patients with giant cell arteritis (GCA) and/or polymyalgia rheumatic (PMR) before…Abstract Number: 2772 • 2014 ACR/ARHP Annual Meeting
The Use of Imaging in the Diagnosis of Polymyalgia Rheumatica: Systematic Literature Review and Meta-Analysis
Background/Purpose ACR/EULAR provisional classification criteria for polymyalgia rheumatica (PMR) incorporate musculoskeletal ultrasound of shoulder and hip (bursitis and synovitis given equal weight). Our objective was…Abstract Number: 2773 • 2014 ACR/ARHP Annual Meeting
Whole-Body MRI Reveals Characteristic Extracapsular Pattern of Inflammation in Polymyalgia Rheumatica
Background/Purpose Polymyalgia rheumatica (PMR) is a disease of widespread musculoskeletal inflammation characterized by pain and stiffness in shoulder and hip girdles. Here we report the…Abstract Number: 2736 • 2014 ACR/ARHP Annual Meeting
Female Specific Increase in T Cell Glycosylation in Lupus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease characterized by altered T cell signaling. SLE is characterized by epigenetic mechanisms that cause hypomethylation…
ACR Meeting Abstracts